For a limited time, you can claim this global database for an unusual 50% off. Act fast, because this offer expires soon.
A contract manufacturing organization (CMO) is a company that provides manufacturing services to cell and gene therapy companies on a contract basis. Contract development and manufacturing organizations (CDMOs) are similar, in that they offer services that include cell therapy product development, manufacturing, clinical trial support, and commercial supply.
Contract Manufacturing for Cell and Gene Therapies
Among cell and gene therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise. Benefits of partnering with a cell or gene therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. This database features companies who specialize in manufacturing and clinical trial support specifically for cell and gene therapies (CGT).
In addition to industry giants that include Lonza, Catalent, WuXi Advanced Therapies, Minaris Regenerative Medicine, and others, there are specialty CDMOs serving the CGT marketplace.
For example, FUJIFILM Cellular Dynamics opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
Similarly, Helixmith, a biotech company with an extensive gene therapy pipeline and a CAR-T program targeting solid tumors, expanded into CDMO services for early-stage CAR-T developers.
In other news, ThermoGenesis launched CDMO services with expertise in CAR-T cells, T cell receptor (TCR), tumor-infiltrating leukocytes (TILs), natural killer cells (NKs), iPSCs, and MSCs.
Anemocyte announced itself as the first BMO (Biotech Manufacturing Organization) in the field of cell and gene therapies. In addition to building 2000 sq. meters of GMP and GMP-compliant facilities for the production of ATMPs, its FLYn’ICE project is using drones equipped with cryogenic pods to achieve temperature controlled transit of cell and gene therapies.
Similarly, Excellos opened its doors with $15M in funding and access to one of the largest cellular material procurement portfolios yet to support cell and gene therapy manufacturing.
In another noteworthy event, RoslinCT, a cell and gene therapy CDMO based in the UK, and Lykan Bioscience, a CDMO focused on cellular therapeutics in Hopkinton, MA, merged to form an international CDMO specializing in advanced therapeutics. The combined entity provides process development expertise and cGMP manufacturing for cell therapeutics, with a specialty in gene editing and iPSC capabilities.
Of course, there have been hefty M&A deals inked within the cell and gene therapy CDMO sector as well. For example, industry behemoth Thermo Fisher Scientific snagged Brammer Bio for an astonishing $1.7 billion, while Catalent acquired Paragon Bioservices for an impressive $1.2 billion and MaSTherCell for $315 million.
Also, Hitachi Chemical Advanced Therapeutics Solutions (HCATS), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. Regenerative Medicine now operate under the joint name of Minaris Regenerative Medicine, while Charles River Laboratories (CRL) acquired Cognate BioServices for a hefty price tag of $875 million. Additionally, Ascend Gene & Cell Therapies raised an impressive $132.5M to launch itself as a CDMO specializing in AVV-based gene therapies.
In late 2023, Bayer opened a $250M cell therapy manufacturing facility to advance regenerative medicines on a global scale. Its 100,000 sq. ft plant was launched to help break current bottlenecks associated with manufacturing transformational cell and gene therapy (CGT) products. Around the same time, Ajinomoto Co. acquired CDMO Forge Biologics for an astounding $620 million to enhance its Bio-Pharma Services business.
More recently, in January 2024, EXO Biologics launched its wholly owned subsidiary, ExoXpertTM, as a CDMO specializing in exosomes. ExoXpert offers a MSC-based exosome manufacturing platform used in European clinical trials.
Database of Cell and Gene Therapy CDMOs
In recent years, CDMOs to advance transformational regenerative medicines have proliferated, with the goal to break the current bottlenecks constraining the production of these novel therapeutics. When you claim this database, you can immediately know the identities of all known cell and gene therapy CDMOs worldwide.
It takes our analysts hundreds of hours of research to uncover these cell and gene therapy (CGT) CDMOs from across the globe and requires the translation of websites in numerous languages. Thankfully, we have a talented, multilingual team who is up to the task. Because we continuously update this database to reflect new competitors entering the marketplace, we are confident that you will find it to be invaluable resource.
If you are a cell therapy developer, you can use this database to identify potential manufacturing partners. If you are a contract manufacturer, you can use it to identify the depth and breadth of your market competition.
The database features:
- Name of company
- Description of cell and gene therapy manufacturing services
- Link to company’s CMO / CDMO services
Use it to:
1) Compare companies capable of manufacturing your cell or gene therapy product
2) Identify market competitors within the cell therapy CMO industry
3) Identify new market entrants offering CMO services
4) Spot countries with a high number of cell and gene therapy CMOs (“geographic hotspots”)
When you check out below, your product will be delivered instantly as an Excel download. Of course, your investment is backed by a Greater than 100% Money Back Guarantee. If you have questions about this product, please email [email protected] for a quick response.
To view License Descriptions, please click here.
Format: Excel File (Delivered Instantly)
No. of Companies: 134 Total
Last Updated: February 26, 2024
*Note: If your company logo is not included in the graphic above, it is still likely to be included in the database. Understandably, 134 company logos could not be fit into this Feature Image.